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 Abstract 
 
Highly active antiretroviral therapy successfully suppresses viral replication and increases 
CD4+ T cell counts in most patients with HIV infection. However, there is a group of patients 
which exhibits discordant treatment responses, with poor CD4 reconstitution despite 
successful viral suppression. The clinical consequences of such immunological failure are 
significant, including both AIDS-related and non-AIDS-related pathology, yet the group is 
poorly characterised. Little is known about why certain patients do not gain the full benefit of 
HAART, and there are consequently few therapeutic options currently available to improve 
their care. 
To investigate relevant aspects of the immunopathology of HIV infection in patients on 
HAART, we have 124 selected patients with persistent viral suppression after 3-9 months of 
HAART and degrees of CD4 reconstitution ranging from no gains at all to normal CD4 
levels. A range of soluble markers of inflammation and apoptosis will be quantified by 
ELISA technique, in serum samples from each patient from before HAART initiation, and at 
6, 12, 24 and 36 months of HAART.  
We will seek correlates between rates of CD4 gain and measured levels of cytokines and 
soluble membrane proteins, during the first 36 months of HAART. Hopefully, the discovery 
of such relationships may further elucidate the mechanisms underlying discordant treatment 
responses in HIV patients, and contribute to improved disease management.
 Introduction 
 
In most HIV patients, highly active antiretroviral therapy (HAART) successfully counters 
disease progression by suppressing viral replication and raising CD4+ T cell numbers.
1
 Thus, 
in clinical practice, plasma HIV RNA levels and CD4+ T cell counts are the key parameters 
in monitoring treatment efficacy. However, some patients exhibit therapy responses in which 
one parameter improves and the other does not, termed discordant. Considering the 
complexity of the interplay between antiretroviral agents, the virus and the immune system, 
such variability in treatment outcomes is unsurprising. Nonetheless, the discordant responders 
clearly warrant further study, as they constitute two as yet poorly characterised groups whose 
therapeutic needs are not sufficiently met. 
 
An indication of the relative neglect of discordant responders is the fact that there are no 
universally accepted definitions for virological and immunological success or failure. 
Consequently, estimates of the frequency of discordant responses vary considerably. A review 
of the limited literature on the subject described frequencies in the range of 20-30% of 
patients between 6 and 24 months after starting therapy.
2-4
 Definitions of virologic success in 
included studies ranged from HIV RNA below 50-1000 copies/mL, while definitions of 
immunologic success included both CD4 gains after a given time and the maintenance of CD4 
levels above a given threshold. 
 
The clinical consequences for patients exhibiting discordant responses have been studied to 
varying degrees. Concerning virologic nonresponders, the evidence is inconclusive,
5
 but many 
studies have established the importance of complete virological suppression for CD4 
reconstitution and long term treatment response.
6-8
 It is therefore fair to assume that improved 
virological response would be beneficial this group. 
 
Incomplete CD4 reconstitution, on the other hand, is clearly of negative prognostic 
significance, associated with an increase in morbidity and mortality due both to AIDS-related 
events and non-AIDS-related events (these include cardio-vascular disease, liver disease and 
cancer).
9-15
 Increased clinical risk has been shown throughout the suboptimal CD4 range, with 
a patient’s overall prognosis only approaching that of an HIV-negative individual at CD4 
levels persistently above 500 cells/mL.
14 
 
A greater understanding of the immunologic characteristics of discordant responders can 
likely contribute to improving the care and thus the prognosis of these patients. An 
opportunity to pursue this goal is afforded us by an extensive HIV patient database at the 
department of Infectious Medicine at Ullevål University Hospital, Oslo. Having treated HIV 
patients since 1983, the department has accumulated clinical data for over 2000 HIV-positive 
individuals, and maintains a bank of frozen serum and plasma samples spanning more than a 
decade.  
 
Utilising these resources, we intend to conduct a study focusing on the discordant group 
apparently representing the most significant clinical problem, those with varying degrees of 
immunologic failure concurrent with good virological responses under HAART. We will 
investigate possible correlates between immune reconstitution in these patients and soluble 
factors, quantified in serum by ELISA technique, representing various aspects of immune 
function and dysfunction in HIV pathogenesis.  
 
 
 Human Immunodeficiency Virus
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To contextualise terms and ideas relevant to our study, this section introduces some 
fundamental aspects of HIV virology and infection. 
 
HIV is in fact two retroviruses of the lentivirus class, HIV-1 and HIV-2, sharing a genetic 
similarity of 40-50%. Both viruses cause AIDS, but HIV-1 is both more pathogenic in the 
individual and is more easily spread between individuals than HIV-2. HIV-1 is the virus 
responsible for the global epidemic of the last three decades, whereas HIV-2 is mostly 
confined to areas of West Africa. HIV-1 is thus the better-studied of the two, and the subject 
of the study to be conducted.  
 
Genome 
The genome is a single stranded molecule of RNA, 9.4 kb (9400 base pairs) in length, present 
in two copies in each virion. When converted to DNA by reverse transcriptase (a hallmark of 
retroviruses), it encodes nine genes. 
 
Proteins 
The nine genes of HIV-1 encode 15 proteins. The three genes gag, pol and env, shared by all 
retroviruses, each give rise to a polyprotein, which after translation are cleaved by proteases 
(gag and pol by the virus’ own protease, env by a cellular protease) to form functional 
proteins: 
 
Gag: p17, p24, p9 (structural proteins) and p6 (budding protein) 
Pol: reverse transcriptase, integrase and protease (enzymes) 
Env: gp120 and gp41 (envelope glycoproteins) 
 
Other HIV proteins are: Tat, Rev, Nef, Vpr, Vpu and Vif (various regulatory functions) 
 
Structure 
The virus particle consists of a core and an envelope. The core consists of the two copies of 
genome associated with a few molecules of RT and integrase along with the viral protease and 
the nucleocapsid protein p9, inside a capsid consisting of p24, which is itself within a 
spherical matrix consisting of p17. The matrix forms a structural scaffolding for the envelope, 
a phospholipid bilayer acquired as the newly created virus buds off from the membrane of an 
infected cell. Anchored in the bilayer is the envelope spike, a structure made up of three 
copies of a gp120/41 heterodimer. 
 
  
                         HIV virion structure               © 2006 Elsevier, Inc 
 
 
The main cellular targets of HIV are CD4-expressing T-lymphocytes, dendritic cells (DCs) 
and macrophages. In addition to the cell surface glycoprotein CD4, a coreceptor is generally 
required for successful viral entry. Chemokine receptors CCR5 and CXCR4 are considered 
the most significant (although the use of several other coreceptors has been observed in vitro), 
and various strains of HIV are classified by their use of one or both as coreceptor.  
 
Viral entry 
The first step is the binding of HIV gp120 to CD4, which induces a conformational change in 
gp120, exposing a binding site for the chemokine receptor. (See (1), figure 2) The binding to 
this coreceptor causes a further change in conformation of gp120, bringing the viral envelope 
into contact with the cell membrane. The gp41 component of the envelope spike induces 
fusion of the two phospholipid bilayers, and the viral capsid is released into the cell 
cytoplasm. (2) 
 
Replication 
On exposure to the cytoplasm, the capsid is removed by host cell proteases, its contents 
forming a preintegration complex, which heads for the nucleus. (3) Inside the complex, the 
viral RNA genome is reverse-transcribed to complementary DNA. (4) The HIV protein Vpr is 
thought to be particularly important in facilitating the transport of the preintegration complex 
into the nucleus. (5) Once inside, integrase inserts the viral cDNA into a random part of the 
host cell genome to form the provirus. (6) 
 
The rate at which the provirus is transcribed depends on whether the infected cell is in a state 
of activation or resting. In a resting T-cell or unactivated DC, the HIV promoter region is 
inhibited by cellular regulators, and only a very limited number of viral mRNAs are 
generated. The number of progeny virions produced in this state of preactivation is negligible. 
However, when the cell is stimulated to activation either by engagement of its T-cell receptor 
 or by proinflammatory cytokines, it initiates the transcription of many of its own genes, 
mediated by cell transcription factors which also bind to the HIV promoter. Viral genes are 
then expressed, including, vitally, the regulatory Tat and Rev. Tat, interacting with several 
host cell factors, counters the aforementioned inhibition of HIV transcription, increasing the 
production of viral mRNAs by a factor of several hundred. (7) Rev is essential for the export 
out of the nucleus of mRNAs encoding viral structural proteins and full-length copies of the 
viral genome. (8),(9) 
 
When mRNAs for the structural, enzymatic and accessory proteins have been translated on 
cellular ribosomes and the resulting polyproteins cleaved by proteases (10), all the elements 
of new virions are ready to be assembled. P24 forms the capsid around the RNA genome and 
core proteins (11) before reaching the cell membrane, budding through it to acquire its 
envelope as the progeny virion leaves the cell. (12) 
 
HIV is cytopathic through a range of mechanisms, and infected cells in which the virus is 
actively replicating can only survive for a short time before undergoing apoptosis. 
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 Clinical course of HIV infection 
 
HIV typically enters the body either through sexual contact or directly via intravenous 
injection. The first cells to be infected if the virus penetrates the rectal or vaginal mucosa are 
usually DCs, macrophages and CD4+ T-lymphocytes in the underlying lamina propria. They 
carry the virus to local lymph nodes, where it finds its way into other resting CD4+ T-cells. 
Over the following weeks, viral replication increases exponentially, as the infection spreads 
through the body’s lymphoid tissues. 2-4 weeks after infection, a significant number of 
patients experience a primary illness, exhibiting symptoms that often include fever, 
lymphadenopathy, fatigue, rash, diarrhoea, headaches and muscular pain. 
 
A vigorous immune response is elicited by the virus, and CD8+ cytotoxic T-cells (CTLs) 
specific for HIV attack the infected cells. This protective response, along with the cytotoxic 
effects of the virus, kills an enormous number of CD4+ T-cells during the acute phase of 
infection, which lasts about 2 months. After this time, viremia subsides, and the chronic phase 
has begun. Concurrently, circulating HIV-neutralising antibodies are detectable in the 
patient’s serum, and he/she is classified as seropositive.  
 
Despite an intense effort on the part of the immune system, HIV is not completely cleared 
from the body in this early phase, and lies dormant as provirus in macrophages and resting T-
cells. A period of chronic infection but clinical latency follows, in which the immune system 
is under perpetual strain. CD4+ T-cells continue to die en masse despite the relative success 
of CTLs and antibodies in suppressing viral levels. Hematopoietic tissues churn out 
replacements at a prodigious rate, but eventually this regenerative capacity becomes 
exhausted, and CD4-levels fall to the point (usually defined as <200 cells/ml blood) where 
they no longer provide a sufficient contribution to the defence against microbial pathogens. 
The opportunistic infections that follow mark the onset of clinical AIDS.  
 
The latency period in HIV infection may last from a few months to over two decades. A host 
of factors predicting progression to AIDS have been documented, relating to characteristics of 
both the patient and the virus involved, and patients on each end of the scale have been 
studied particularly. Those who in the absence of anti-retroviral treatment stay AIDS-free for 
over 10 years are referred to as long-term non-progressors (LTNP), while those who develop 
clinical disease within two years of infection are called rapid progressors (RP). 
 
 HAART 
 
Whether disease progression is slow or rapid, HIV infection without treatment is, eventually, 
almost invariably fatal. While the first HIV drug, zidovudine/azt, was introduced in 1987, it 
was not until 1996 and the advent of combination anti-retroviral therapy that HIV’s assault on 
the immune system could be combated to any significant extent. By combining several anti-
retroviral drugs with different mechanisms of action, viral replication can be reduced in most 
patients to a point at which the body is able to reconstitute its CD4-levels and thus immune 
function. 
 
The drugs currently licensed for use can be divided into four groups by mechanism of action: 
 
Nucleoside RT inhibitors (NRTIs): competitively inhibit the deoxynucleosides being strung 
together to form viral DNA by reverse transcriptase, prematurely terminating the chain. 
 
Non-nucleoside RT inhibitors (NNRTIs): induce conformational changes in RT, inactivating 
it. 
 
Protease inhibitors (PIs): competitively bind to the active site of viral protease, hindering 
post-translational cleavage of the gag and pol polyproteins. 
 
Fusion inhibitors: enfuvirtide, the only molecule in use to date, binds to gp41, blocking the 
conformational change which otherwise occurs after gp120 binds to CD4. This prevents the 
viral envelope from fusing with the cell membrane. 
 
Highly active anti-retroviral therapy (HAART), as it is commonly referred to today, has 
turned HIV infection into a chronic but relatively stable condition, though only in the 
countries that can afford to offer it to patients. In addition to a price which is prohibitive in 
those parts of the world where the treatment is most desperately needed, HAART is 
demanding of the recipient, requiring near-perfect compliance to effectively suppress viral 
replication and avoid resistance development. The complicated daily regimens and large 
numbers of pills involved, along with the significant short and long-term side-effects of the 
drugs severely test a patient’s motivation. 
Clearly, the ideal solution, and one which has been pursued intensely since the discovery of 
the virus, is a vaccine. The goal of bestowing protective immunity against HIV has, however, 
proved elusive.  
 
Immunopathology 
 
Our study aims to further elucidate aspects of the interplay between HIV and the immune 
system. This section briefly presents some fundamental elements of the immunopathology of 
the virus, including some recently established key insights. 
 
T-helper cells (Th cells) are required for the orchestration of an effective immune response, 
through cytokine production and direct interaction with and activation of CTLs. The 
preferential infection and killing of this cell population by HIV eventually cripples the 
defense against microbial infections and many tumours, and is the main marker of disease 
progression. A phenomenon of key importance, however, is that the loss of Th cells extends 
far beyond those actually infected by virus. Several mechanisms have been suggested to 
explain this loss, including upregulation of several pro-apoptotic membrane proteins on 
infected cells and interference with T cell maturation. An observation which has proved 
 highly significant is that the majority of Th cells lost through all phases of HIV infection are 
from the gastrointestinal tract. This has been linked to the persistent immune activation of 
chronic HIV infection.  
 
HIV-specific CTLs kill infected CD4+ cells by perforin/granzyme-mediated cytolysis and 
release soluble factors which inhibit viral replication, such as RANTES (CCL5), along with a 
range of other cytokines. In the acute phase of infection, the CTL response is vigorous, but as 
the disease progresses and Th function is lost, CTL response suffers accordingly. An 
additional pressure on the CTL population is the frequent generation throughout the disease 
course of so-called genetic escape mutants, HIV viruses displaying new epitopes. This is a 
result of the high error rate of viral reverse transcriptase along with the frequently high rate of 
replication of HIV. Consequently, ever new CTL clones are activated, over time causing 
clonal exhaustion. 
 
A new concept in relation to T-cell responses is that of polyfunctionality and response quality. 
It was discovered that HIV non-progressors had T cells which exhibited the ability to perform 
many functions at once (i.e. release many different cytokines and perform cytolysis), 
compared to progressors. This response quality has correlated better with viral suppression 
than T cell quantity. The induction of such polyfunctional T cell responses has become a goal 
in vaccine development. 
 
Another consequence of the high mutation rate of HIV is the relative inefficacy of the 
humoral immune response, that mediated by antibodies. The virus is present in so many 
antigenic varieties that a neutralising antibody response becomes impossible. In addition, it is 
thought that key epitopes in the proteins of the viral envelope are sterically obscured, 
hindering those antibodies that would bind the virions between cells from doing so. Finally, 
multiple clones of B cells are activated by gp120 acting as superantigen, producing antibodies 
which have no effect against the virus. As with CTLs, this is thought to cause clonal 
exhaustion, constituting yet another immune defect in advanced disease. 
 
Chronic immune activation is a fundamental feature of progressive HIV infection, and has 
numerous deleterious consequences. Already mentioned is the polyclonal activation of both B 
and T cells, putting strain on their homeostatic mechanisms. Over time elevated levels of 
proinflammatory cytokines damage lymphoid tissues, including the thymus, site of T cell 
maturation. Most detrimental is probably the fact that the large numbers of T cells being 
activated throughout the disease are prime targets for the virus to infect. 
 
The reason for this immune activation has recently been linked to the clinically apparent 
enteropathy that has long been recognised in HIV infection. The GI tract normally houses the 
majority of the body’s lymphocytes, but it has been found that during acute HIV infection, 
most of the CD4+ cells there are killed directly by viral infection. This local depletion 
continues throughout the disease course. At the same time, there is increased apoptosis of 
enterocytes and increased intestinal permeability. Recently, increased levels of 
lipopolysaccharide have been found in the blood of HIV-infected individuals, indicating a 
translocation of microbial products across the damaged intestinal mucosa. While the 
immunostimulatory effect of LPS is mediated first and foremost via Toll-like receptor 4, it is 
assumed that other microbial products similarly enter the blood-stream, activating the immune 
system through other means. 
 
 
 Methods 
 
Subject of investigation 
Our study question can be summarised as follows: Is there a correlation between CD4 
reconstitution in patients on HAART with undetectable HIV-1 viral loads and soluble markers 
of inflammation and apoptosis? 
 
Patients 
We have selected patients from the HIV database at the Department of Infectious Medicine at 
Ullevål Hospital who meet the following inclusion criteria:  
- initiated HAART after 01.01.2000 
- achieved viral suppression to undetectable levels (<50 copies/mL) within 3-9 months 
of HAART initiation 
- maintained viral loads under the limit of detection throughout the study period, 
allowing for single blips. 
- no AIDS-defining events before or during the study period 
 
Time period 
Serum samples have been selected, where available, at baseline (last available sample before 
initiation of HAART) and at 6, 12, 24 and 36 months after HAART initiation. No samples 
dating after November 2007 are available, as serum/plasma storage for research purposes at 
the department ended at that time. The number of samples available for each patient varies 
from 2 to all 5 points in time. 
 
Soluble factors 
At the time of writing, the final decision about which soluble factors are to be investigated is 
yet to be made. Several issues influence this choice. 
 
Firstly, we are fortunate enough to be working with a laboratory which performs ELISA 
analyses with a high degree of automation, handling large volumes of samples 
simultaneously. This reduces analysis time and cost, enabling us to choose several soluble 
factors to analyse. 
 
On the other hand, the number and variety of analyses is limited by the amount of sample 
material available, 2 vials of frozen serum for each patient from any given time point. 
 
Additionally, we are limited in our choice by the time and likely suboptimal temperature at 
which the samples have been frozen. For the results of the ELISA analysis to be reliable, we 
must choose soluble markers known to be robust when frozen over long time periods. 
 
Many molecules are of interest:
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RANTES (Regulated upon Activation Normal T-cell Expressed, and presumably 
Secreted): also known as CCL5, this chemokine is secreted by activated T lymphocytes and 
is chemotactic for other T cells, eosinophils and basophils. Along with MIP-1-α and -β, it is a 
ligand for the CCR5 chemokine receptor, and thus functions as an HIV inhibitory factor by 
preventing viral entry into cells. 
 
MIP-1-α and MIP-1-β: also known as CCL3 and 4, respectively, these two chemokines are 
produced by macrophages when stimulated by bacterial lipopolysaccharide. They contribute 
 to local inflammatory responses by activating granulocytes, and together with RANTES 
inhibit HIV entry into cells. 
 
TNF (Tumor Necrosis Factor): Secreted by monocytes, macrophages, neutrophils, NK cells 
and certain T cells upon stimulation by LPS and a range of cytokines, including interferons 
and interleukin 2. This key inflammatory cytokine has specific receptors on nearly all cells in 
the body, and a wide range of biological effects. Chronically raised levels of TNF play a role 
in the chronic immune activation of HIV infection. Also of interest would be measuring 
circulating levels of soluble TNF receptor, or TNF-BF (TNF-Blocking Factor), believed to 
regulate TNF effects by preventing the cytokine’s interaction with cell receptors. 
 
TRAIL (TNF-Related Apoptosis-Inducing Ligand): Part of the TNF ligand superfamily, 
this cytokine can induce apoptosis by binding to Death Receptors 4 and 5. There is evidence 
to suggest that HIV-induced expression of TRAIL by antigen-presenting cells contributes to 
the extensive apoptosis of uninfected CD4+ T cells.
18 
 
sFas/sFasL: Fas is an important component of the extrinsic pathway of programmed cell 
death. HIV-infected cells upregulate their expression of Fas ligand, inducing apoptosis of 
their uninfected neighbours.
16
 Soluble Fas and Fas ligand are often elevated in HIV infection, 
possibly evidence of Fas-mediated depletion of CD4+ T cells.
19 
 
IL (interleukin)-17: Contributing to enterocyte homeostasis, this cytokine is expressed by a 
population of Th cells (Th17) which is preferentially lost from the GI mucosa in HIV 
infection.
20
 This may contribute to the increased permeability to microbial products such as 
LPS which is implicated in chronic immune activation and HIV disease progression. 
 
IL-18: Expressed in a variety of immune cells, this proinflammatory cytokine induces the 
expression of IFN-γ, which in turn promotes so-called Th1 responses as well as upregulating 
Fas-expression. 
 
IL-7: Synthesised by stromal cells in the bone marrow and thymus, IL-7 has been identified 
as an important growth factor for T cells. IL-7 levels tend to be elevated in HIV patients and 
inversely correlated with CD4 counts,
 21
 indicating the existence of a direct feedback loop that 
may be critical to CD4 reconstitution under HAART. 
 
 
 ELISA 
 
The soluble factors under investigation will be quantified in the serum samples by ELISA, at 
the laboratory of the Research Institute for Internal Medicine at Rikshospitalet, Oslo. 
 
ELISA, or enzyme-linked immunosorbent assay, is a powerful and widely used method to 
detect and measure concentrations of specific proteins in complex mixtures. Developed in the 
1970s as an immunological tool, it has also found use in medical diagnostics, toxicology and 
quality-control in various industries. 
 
While many variations on the method exist, the fundamental elements are:
 22 
 
1. Coating/capture: The antigen is immobilised in a well of a microtiter plate, either directly, 
that is, by passive adsorption (in a traditional ELISA), or by the use of a capture antibody (in 
“sandwich” ELISA). The capture antibody is specific for the antigen of interest, and promotes 
the preferential binding of this antigen in the well. This is useful where the antigen is in a 
complex solution with many other proteins(such as serum/plasma?) 
 
2. Plate blocking: To prevent non-specific binding of the detection antibody and/or 
secondary antibody (if used) to the well, all vacant binding sites are covered by an irrelevant 
protein or other molecule, often bovine albumin. 
 
3. Probing/detection: An antigen-specific detection antibody is added to the wells, forming a 
high-affinity bond to the antigen. In direct ELISA, the detection antibody is tagged with an 
enzyme which catalyses the colour change to be measured. In indirect ELISA, by contrast, the 
enzyme is attached to a secondary antibody which binds the Fc-fragment of the detection 
antibody. This enables an amplification of the signal, improving the sensitivity of the assay. 
Then a solution of a chromogen substrate for the enzyme is added, and a coloured product is 
generated, in an amount proportional to the concentration of antigen present in the sample. 
 
4. Signal measurement: The intensity of the colour change is measured by a 
spectrophotometric plate reader, and the concentration of antigen extrapolated from a standard 
curve for the assay. 
 
 
Some typical ELISA configurations         © 2010 Thermo Fisher Scientific 
 
 
 In our study, samples will be analysed by sandwich ELISA, using Horse Radish Peroxidase 
(HRP) as the enzyme tag. For each assay, antibodies and antigens standards need to be 
purchased. The quantitation of certain soluble markers, such as IL-7, may require the use of 
specific, high-sensitivity kits, with special signal amplification. 
 
For each assay, a standard curve will be generated by analysing serial dilutions of a known 
concentration of reconbinant antigen, to which the sample signals may be compared and 
antigen concentations extrapolated. 
 
 
 
Example of an ELISA standard curve      © 2006 Elsevier, Inc. 
 
 
 
Statistical analysis 
 
The possible correlation between ΔCD4 (CD4 reconstitution from baseline) and the quantities 
of soluble factors at each time point will be investigated using parametric statistical methods. 
The main prerequisite for using parametric methods is that we can assume that the sample is 
normally distributed, which depends upon the types of variables in our data set and n, the size 
of our sample.  
 
If the necessary assumptions about normal distribution can be made, parametric statistical 
methods are preferable to non-parametric methods because they are more sensitive in 
uncovering statistical relations between the variables.  
 
 
 Progress 
 
149 patients conformed to the selection criteria, but 25 had to be eliminated from the study 
due to missing samples. Thus, at the time of writing, a total of 520 serum samples from 124 
patients have been selected, and are to be sent to Rikshospitalet for analysis as soon as the 
final decision has been made regarding the markers to be investigated. 
 
 
Remaining work 
 
A sample size of 124 patients is most likely large enough to allow the use of parametric 
statistical methods to explore the data from the ELISA (marker concentrations) analyses and 
the HIV database (CD4 counts and time periods). 
 
We will seek statistically significant differences in levels of soluble factors between patients 
exhibiting different levels of immunological response to HAART. Combined with existing 
knowledge about the roles of these signalling molecules and receptors in normal immune 
function and HIV pathogenesis, such correlates may hopefully contribute to improved care for 
immunologically discordant patients in the future. 
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